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ABSTR ACT: The paper focuses on the degree to which the accounting treatment of R&D
expenditure is stock price informative following the adoption of IAS. Therefore, using recent data
of French listed companies, starting from the year in which IFRS were applied, 2005-2015, the
present study examines the value relevance of the different R&D accounting treatments. Unlike
evidence regarding the pre-IFRS period in France, we find that the capitalized portion of R&D
is not correlated with market values, suggesting that under IFRS mandatory implementation,
R&D assets are not value relevant. The expensed portion of R&D is positively related to market
values only for manufacturing companies. Accordingly, we conclude that IFRS implementation
has implications on the valuation of R&D expenditure by investors in French firms.
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1. INTRODUCTION
Since the mandatory implementation of International Financial Reporting Standards
(IFRS) by listed European companies in 2005, the consolidated financial statements
are published in accordance with international accounting standards. The main goal
is to provide a common accounting language and ensure greater consistency in the
presentation of accounting information in response to the growing internationalization of
financial markets. In some European countries such as Germany, Austria and Switzerland,
the adoption of international standards was voluntary before 2005. This was not the case
for French companies, and the possibility of preparing their accounts according to rules
other than national standards, Generally Accepted Accounting Principles (GAAP), was
not included in the law. It therefore seemed appropriate to study the consequences of the
introduction of IFRS on French companies.
Our objective is to highlight the effects on market value of accounting treatment for a
specific asset class, namely the research and development (R&D) expenses, given it is
affected by the mandatory change. Before IFRS adoption in France, the rules impose the
1 Tunis El Manar University, Tunis, e-mail: chaibihasna@gmail.com
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immediate recognition of R&D expenditure as a cost, unless the R&D project meets certain
conditions. The French rules (GAAP) stipulate that R&D expenses can be exceptionally
an intangible asset only if they relate to a specific individual project with a real chance of
technical success and economic profitability and whose costs can be obviously determinate.
Nevertheless, since 1 January 2005, the accounting treatment of R&D expenditure under
IAS2 38 becomes different. Actually, the capitalization of R&D expenses, which was
an option treatment under French GAAP, has become an obligation under IFRS. The
capitalization of R&D expenses is a consequence of the standard’s requirements and not
manager’s choice. As a result, the development phase of an intangible project should be
recognized once six criteria are met3.
In the accounting literature, the controversy over intangible assets and particularly R&D
expenditure has been present in the accounting debate since several decades (Aboody and
Lev, 1998; Lev and Sougiannis, 1996; 1999). Numerous studies provide evidence about
the relevance of capitalized R&D expenditure during the period before the transition
to IFRS. Zhao (2002) shows that R&D expenses are not value relevant, while Oswald
(2008) proves little difference between the value relevance of the expensed and capitalized
portion of R&D expenditure. However, few studies have investigated the period following
the mandatory adoption of IFRS. We can mention the study of Shah et al. (2013) that
examines the value relevance of R&D expenditure in the periods before and after IFRS in
the UK. More recently, Gong and Wang (2016) estimate the changes in the value relevance
of R&D expenses for periods pre-IFRS and post-IFRS adoption in countries that previously
mandated immediate expensing against those that allowed optional capitalization of R&D
expenditure ones.
Indeed, there are studies that have investigated the value relevance of R&D expenses in
France. Ding and Stolowy (2003), for instance, reveal the lack of relevance regarding
the decision to capitalize R&D expenses in relation to the market value of the French
company. Later, Cazavan-Jeny and Jeanjean (2006) provide evidence suggesting that R&D
expenditure, in France, are negatively associated with market value. Nevertheless and to
the best of our knowledge, there is no study focusing on the post-IFRS period in France.
On that basis, we contribute to the R&D accounting literature by adding an empirical study
examining the value relevance of R&D assets and expenses after the mandatory transition
2 International Accounting Standards.
3 IAS 38 Development Capitalization Criteria stipulate: “An intangible asset arising from development (or
from the development phase of an internal project) shall be recognized if and only if, an entity can demonstrate
all of the following:
(a) The technical feasibility of completing the intangible asset so that it will be available for use or sale.
(b) Its intention to complete the intangible asset and use or sell it.
(c) Its ability to use or sell the intangible asset.
(d) How the intangible asset will generate probable future economic benefits. Among other things, the entity can
demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it
is to be used internally, the usefulness of the intangible asset.
(e) The availability of adequate technical, financial and other resources to complete the development and to use
or sell the intangible asset.
(f) Its ability to measure reliably the expenditure attributable to the intangible asset during its development.”
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to IFRS in France, where companies are required to activate whether the capitalization
criteria are met compared to the discretion available in the past.
In this regard, Lev and Zarowin (1999) provide that it is necessary to control the industry
effects in any study on the R&D costs, because these expenses are specific to the nature
of sectors. Companies operating in different sectors have different behaviors in terms of
investment in R&D. As a consequence, the second objective of this study is to examine the
separate value relevance of R&D across manufacturing and nonmanufacturing sectors in
the post-IFRS period. To pursue these objectives, we employ recent data by focusing on
the fiscal years from 2005 to 2015 of listed French firms with R&D activity. We find that the
capitalized portion of R&D is not related to market values, with no significant differences
across manufacturing and nonmanufacturing firms. Nevertheless, the expensed portion
of R&D is positively related to market values of manufacturing companies.
The remainder of the paper is structured as follows. Section 2 exposes the R&D treatment,
related literature and the development of the research hypotheses. Section 3 presents
the details of the research methodology, related valuation models and the data selection
process. Section 4 provides the results of the empirical analysis and discussion of the main
findings. Finally, Section 5 concludes the study.
2. INSTITUTIONAL BACKGROUND, PRIOR LITERATURE, AND
HYPOTHESES
2.1. R&D EXPENSES TREATMENT : BEFORE VS. AFTER IFRS ADOPTION
The accounting treatment of R&D expenditure is controversial at an international level.
For example, International Accounting Standard (IAS 38) permits the capitalization
of development expenditures when certain conditions are met, whereas the US GAAP
adopts a stricter approach to the issue. Indeed, the Financial Accounting Standards
Board (FASB), which initially authorized the activation of R&D expenditure, adopted an
approach in October 1974 with SFAS No. 22 (FASB 1974, §12), which requires all R&D
expenses are expensed during the period of their commitments. The only exception is
SFAS No. 863, which concerns software. The same approach was adopted in 1998 by the
Business Accounting Deliberation Council, requiring Japanese firms to cover all their
R&D expenditure. However, certain national accounting standards such as the French
one, offer some flexibility to allow the capitalization of R&D costs when certain conditions
are simultaneously fulfilled, namely:
- The product is well defined ;
- The feasibility of the product is confirmed ;
- The related costs can be identified ;
- The costs can be covered through the revenues generated by the exploitation of the
project.
- The firm intends to market the product.
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The French regulations concerning the treatment of R&D expenditure have undergone
numerous changes for the consolidated financial statements. Since 2005, all listed
companies in the European Union (EU) have been obliged to prepare their annual reports
in accordance with international standards (IFRS/IAS). The revised IAS 38 distinguishes
between a “research phase” and a “development phase”. Research costs must be recognized
as an expense when incurred. The revised IAS 38 (§55) considers that a company cannot
demonstrate the existence of an intangible asset during the search phase of a project that
will generate probable future economic benefits. Nevertheless, development costs are
recognized as assets, if and only if the company can demonstrate simultaneously a set of
conditions. Actually, IAS 38 Development Capitalization Criteria stipulate: “An intangible
asset arising from development (or from the development phase of an internal project)
shall be recognized if and only if, an entity can demonstrate all of the following: “
a. The technical feasibility of completing the intangible asset so that it will be available for
use or sale.
b. Its intention to complete the intangible asset and use or sell it.
c. Its ability to use or sell the intangible asset.
d. How the intangible asset will generate probable future economic benefits. Among
other things, the entity can demonstrate the existence of a market for the output of
the intangible asset or the intangible asset itself or, if it is to be used internally, the
usefulness of the intangible asset.
e. The availability of adequate technical, financial and other resources to complete the
development and to use or sell the intangible asset.
f. Its ability to measure reliably the expenditure attributable to the intangible asset during
its development.”
Although the accounting treatment of R&D expenditure under IFRS appears similar to
French GAAP, there is an important disparity. Actually, IFRS requires the capitalization
of the R&D expenditure which meets specified criteria, while the French GAAP provides
an option to capitalize that R&D expenditure.
2.2. RELATED LITERATURE ON THE VALUE RELEVANCE OF R&D EXPENSES
AFTER IFRS TRANSITION
Even today, the accounting treatment of R&D expenses still a sensitive issue. Most of the
empirical studies focusing on the value relevance of R&D costs investigated the period
before the implementation of IFRS (e.g. Zhao, 2002; Ding and Stolowy, 2003; CazavanJeny and Jeanjean, 2006). However, research that has examined the issue of the value
relevance of R&D expenditure (capitalized or expensed) in considering the post-IFRS
effects is limited. At this day, the related major studies can be summarized in Tsoligkas
and Tsalavoutas (2011), Shah et al. (2013) and Gong and Wang (2016).
Tsoligkas and Tsalavoutas (2011) assess value relevance of R&D in the UK after IFRS
mandatory implementation. The results reveal that the capitalized portion of R&D is
positively related to market values, which implies that the stock market absorbs these
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assets to successful projects promising future economic benefits. Nevertheless, they report
a negatively correlation between expensed R&D costs and market value under IFRS,
supporting the idea that theses portions of assets do not reflect any future economic benefit
and should be expensed. Consequently, the transition to IFRS induced implications for
the valuation of R&D expenditure in the UK.
Afterward, Shah et al. (2013) continue the research of Tsoligkas and Tsalavoutas (2011),
limited to the first three years post-IFRS (2006-2008), by extending the sample period to
seven years after adopting IFRS, 2005-2011. This study also examines the impact of the size
of companies and sectors on the value relevance of R&D during the period between 2001
and 2011 in the UK, by separating the periods before and after IFRS. The results affirm
the value relevance of the capitalized R&D costs in the 11 years of the sample period.
However, no improvement is recorded at the R&D capitalized value relevance in the postIFRS period. Large companies have a higher relevance of the R&D expenses capitalized
than small firms. However, the sector specification does not appear to have a significant
effect on the relevance of R&D costs.
Recently, Gong and Wang (2016) test whether the nature of differences between national
GAAP and IFRS rises to differential changes in the value relevance of R&D expenses after
the adoption of IFRS across nine countries4, covering pre-IFRS and post-IFRS periods
during 1997–2012. They find that the value relevance of R&D expenses declines after IFRS
adoption in countries that previously mandated immediate expensing or allowed optional
capitalization of R&D expenditure. They do not find change in the value relevance of R&D
costs for countries that convert from the mandated capitalization of R&D expenditure to
IFRS. However, even Gong and Wang (2016) integrate the French context in the group of
the countries examined, their study presents a subtle limitation. Actually, they have not
available data on capitalized R&D assets. As a result, one cannot draw conclusions about
how different accounting treatments of R&D, capitalization versus expensing, affect the
value relevance of R&D costs.
Therefore, we will try to contribute to the existing literature on accounting by examining
whether there is a value relevance of R&D costs (expensed or capitalized) in the post-IFRS
period in France for a recent sample of 11 years during 2005-2015. Moreover, this study
provides evidence on industry membership impact by investigating potential differences
in the relevance of R&D expenditure (expensed or capitalized) between manufacturing
companies and nonmanufacturing ones.
2.3. HYPOTHESES DEVELOPMENT
Stark (2008) and Wyatt (2008) argue that the adoption of IFRS would decline the value
relevance of R&D treatment. The point of view advanced by Stark (2008) is that the
4 The nine countries are Australia, Finland, France, Germany, Netherlands, Norway, Sweden, Switzerland,
and the UK. These countries adopted IFRS since 2005.
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adoption of IFRS would eliminate discretion in the treatment of R&D expenditure, so
would remove a useful way that companies communicate information to stock markets.
The capitalization of R&D expenditure was treated as a signal to the market to indicate
the quality of R&D spending. Under French GAAP rule, opting for capitalization reflects
a management decision for the purpose of transmitting a signal on their profitable R&D
projects for the market and distinguishes themselves from competitors. Actually, the
major difference between pre-IFRS and post-IFRS, in particular IAS 38, is that in the
former case, management has discretion to choose to either capitalize or expense the
development costs, while in the latter case, managers are required to capitalize R&D
expenditure (development costs) once certain criteria are met. In other words, reported
R&D expenses are effectively value relevant under the optional capitalization rule, and not
in the context of a mandatory adoption. This argument is consistent with that of Wyatt
(2008), who suggests that the most discretionary elements of intangible assets are the most
relevant, due to discretion in the accounting treatment. As a result, we expect an absence
of the value relevance of R&D expenses after the mandatory capitalization rule.
H1. R&D expenditure (expensed or capitalized) has no value relevance in the post-IFRS
period.
Another important point of discussion in accounting literature is whether the impact of
value relevance of R&D costs is different across diverse sectors. Examining manufacturing
versus nonmanufacturing firms, Shah et al. (2008) find positive and significant effects of
R&D expenditure on market value for both sectors. Nevertheless, Shah et al. (2009) reveal
clear-cut sector effects, and present that, compared to nonmanufacturing companies,
manufacturing ones are likely to adopt an intensive investment in R&D strategy to
maximize their market value. Actually, Ho et al. (2005) explain that manufacturing and
nonmanufacturing firms are likely to adopt a different mix of R&D and advertising
investments because of the differences in their relative impacts. They argue that while
nonmanufacturing firms benefit most from advertising investment for value creation
purposes, manufacturing ones are likely to choose a more R&D-intensive strategy beside
advertising investment to maximize their market value. Later, and by splitting R&D
expenditure into capitalized and expensed portions, Shah et al. (2013) report that, in the
case of the big companies, capitalized R&D portion is positively and signiﬁcantly related
to market value for both nonmanufacturing and manufacturing sectors. However, when
the coefficient for nonmanufacturing sector is signiﬁcant and negative, it is insigniﬁcant
for manufacturing sector. On the other hand, capitalized R&D is positively signiﬁcantly
related to market value of the small manufacturing companies, but there is a negative and
significant relationship between expensed R&D and market value for nonmanufacturing
ﬁrms.
As a result, one would not draw consistent conclusion, on the bases of the mixed findings
above, confirming if manufacturing or nonmanufacturing firms are associated with a
higher R&D relevance.
H2. The industry membership has no effect on the value relevance of R&D expenditure.
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3. RESEARCH DESIGN
3.1. METHODOLOGY

1

To examine the value relevance of accounting figures, we follow most prior studies
(Cazavan-Jeny and Jeanjean, 2006; Oswald, 2008; Tsoligkas and Tsalavoutas, 2011; Shah
et al., 2013) that have adopted Ohlson valuation model (1995). The idea is based on the
principle that firms' accounting numbers are judged to be ‘value relevant’ if they are
significantly related to their market value (Beaver, 2002). Actually, Ohlson considers the
market value of a company as function of book value of equity and expected future
residual income. Consequently, the fundamental Ohlson (1995) valuation framework will
be the bench mark model throughout the study. In its simple form, the market value of a
company is represented by a linear function of its book value of equity and net income:
𝑀𝑀𝑀𝑀!" = 𝛼𝛼! + 𝛼𝛼! 𝐸𝐸!" + 𝛼𝛼! 𝐵𝐵𝐵𝐵 + 𝜀𝜀!"

(1)

Where, MVit is the market value for company i at time t (the market capitalization of the
company), which is measured four months after the end of the year for each company54. Eit
is the earnings of company i at time t. BVit stands for book value of equity of company i at
time t. εit is an error term.
Barth et al. (2001) highlight that the main advantage of Ohlson model is that earnings and
book value of equity can be divided to examine the value relevance of separate accounting
numbers. In our study, we follow prior research (Cazavan-Jeny and Jeanjean, 2006;
Tsoligkas and Tsalavoutas, 2011; Shah et al., 2013) and we decompose accounting
incomes into: (1) earnings before R&D expenses and (2) the amount of expensed R&D.
Similarly, we divide book value of equity into (1) the book value before capitalized R&D
and (2) the amount of R&D in the assets. Therefore, the impact of capitalized R&D and
expensed R&D on market value is isolated from earnings and book value of equity and the
following equation is formed:
𝑉𝑉𝑉𝑉!" = 𝛽𝛽! + 𝛽𝛽! 𝐴𝐴𝐴𝐴!" + 𝛽𝛽! 𝐴𝐴𝐴𝐴𝐴𝐴!" + 𝛽𝛽! 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶!" + 𝛽𝛽! 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸!" + 𝜀𝜀!"

(2)

Where, MVit is the market value for company i at time t. 𝐴𝐴𝐴𝐴!" is the adjusted earnings for
firm i in year t, before the processing of R&D expenditure. 𝐴𝐴𝐴𝐴𝐴𝐴!" represents the adjusted
book value of equity for firm i in year t, which is net of capitalized R&D. 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶!" is the
annual amount of capitalized R&D costs. 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸!" is the annual amount of expensed
R&D costs. εit is an error term.
In order to control the model for heteroscedasticity problem, MV, 𝐴𝐴𝐴𝐴, ABV, 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶,
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 variables are deflated by the number of outstanding shares. Barth and Kallapur
(1996) and Barth and Clinch (2009) show that the number of outstanding shares is an
54 Actually,
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effective proxy to capture the effect of scale65. By this way, we measure all variables of the
regressions on a per share basis.
capture the effect of scale5. By this way, we measure all variables of the regressions on a per
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conclude that employing number of outstanding shares as deflator is more effective to examine the scale
effects as compared to book value of equity.
8
6 Barth and Clinch (2009) try both book value of equity and number of shares as deﬂator, and they conclude
that employing number of outstanding shares as deﬂator is more effective to examine the scale effects as
compared to book value of equity.
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Deflating the variables of the models by the number of outstanding shares certainly
produces extreme values. In order to mitigate the effect of extreme outliers, we winsorize
the sample variables and ratios at the top and bottom one percentile of their respective
distributions.
To recuperate the necessary data, we directly use the electronic sites of companies to
download the annual reports (or references) issued by companies or the website of the
World Library of Annual Reports (www.annupedia.com). We collect stock prices to assess
the market value of sample firms from the ABC Stock Exchange website.
3.3. DESCRIPTIVE STATISTICS
Table 1 presents the sample distribution of the variables included in the study during the
period from 2005 to 2015. What really stands out from this table is that expensed R&D
costs are, on average, higher than the capitalized R&D expenses. This finding proves that
French companies are more likely to expense the costs of R&D than capitalizing them in
the period after IFRS mandatory implementation. Moreover, Table 1 reveals that there is
a significant disparity in the intensity of R&D expressed by the remarkable difference in
standard deviation of the variables CapRD and ExpRD.
Table 1: Descriptive statistics of variables over the period 2005-2015
Variable
MV
AE
ABV
CapRD
ExpRD

Number of
observations
396
396
396
396
396

Mean

Median

Std. dev

Min

Max

1.975
1.298
0.199
0.018
0.080

1.537
0.831
0.092
0.000
0.024

3.549
1.905
0.405
0.032
0.111

0.002
-0.064
-0.903
0
0.004

39.532
17.206
2.249
0.171
0.611

MV is the market value. AE is the adjusted earnings before the processing of R&D expenditure. ABV
represents the adjusted book value of equity net of capitalized R&D. CapRD is the annual amount of
capitalized R&D costs. ExpRD is the annual amount of expensed R&D costs. All variables are deflated by
the number of ordinary outstanding shares.

Table 2 exposes the descriptive statistics of both R&D variables by industry from 2005
to 2015. The values of CapRD and ExpRD of manufacturing companies are, on average,
significantly higher than in the nonmanufacturing sector, which let us conclude that the
manufacturing firms spend more in R&D activity that the nonmanufacturing ones.
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Table 2: Descriptive statistics of R&D variables by sectors
Variables

CapRD
ExpRD

Number of
observations
Manu
Nonmanu
297
99
297
99

Mean
Manu
0.045
0.217

Nonmanu
0.009
0.110

Std. dev
Manu
0.090
0.292

Nonmanu
0.015
0.171

Difference
0.036
0.107

P>|t|
0
0.001

CapRD represents the annual amount of capitalized R&D costs; ExpRD represents the annual amount of
expensed R&D costs. All variables are deflated by the number of ordinary outstanding shares.

Table 3 shows the correlations among the regression variables. All independent variables,
adjusted earnings, adjusted book value of equity, capitalized R&D costs and expensed
R&D costs, are positively related to the dependent variable, market value of equity. We can
also notice that these variables have a value of VIF “Variance Inflation Factor” that is less
than 107, which allow us to conclude that our empirical model does not have a potentially
problem of multicollinearity. Furthermore, the highest correlation coefficient is 0.6847,
and it is between market value of equity and earnings.
Table 3: Correlation matrix and VIF
Variable
MV
AE
ABV
ExpRD
CapRD

MV
1.0000
0.6847
0.5962
0.2265
0.1632

AE

ABV

1.0000
0.4428
0.2594
0.1318

1.0000
0.2300
0.1887

ExpRD

1.0000
0.1998

CapRD

VIF

1/ VIF

1.0000

1.96
1.65
1.32
1.21

0.510
0.606
0.757
0.826

MV is the market value. AE is the adjusted earnings before the processing of R&D expenditure. ABV represents
the adjusted book value of equity net of capitalized R&D. CapRD is the annual amount of capitalized R&D
costs. ExpRD is the annual amount of expensed R&D costs. All variables are deflated by the number of ordinary
outstanding shares.

4. EMPIRICAL RESULTS
4.1. RESULTS FOR THE VALUE RELEVANCE OF R&D AFTER IFRS
IMPLEMENTATION
We test two different models. Model (1) is employed to estimate the fundamental Ohlson’s
(1995) model explaining market value of equity by earnings and book value of equity.
Table 4 shows that the model is statistically signiﬁcant under 1% level by using F-test. For
this basic model, the coefficient on earnings, E, is statistically close to 2, and the coefficient
on capital equity, BV, is roughly equal to 1. Earnings and book value of equity are positively
signiﬁcantly related to market value. This finding is consistent with prior research which
7 A limit suggested by Gujarati (1995) and Kennedy (1998).
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examined the value relevance of R&D in France prior to 2005 (e.g. Cazavan-Jeny and
Jeanjean, 2006; Gong and Wang, 2016), indicating that accounting numbers are strongly
associated with share prices (adjusted R2 is relatively high, 65%).
Model (2) is employed to examine the value relevance of R&D expenditure for the sample
from year 2005 to 2015 (table 4). It is similar to model (1) except that we isolate the effect
of both capitalized and expensed R&D on market value of equity. This decomposed
model allows us to highlight the portion of capitalized R&D (CapRD ) and expensed
R&D (ExpRD). Model (2) has four independent variables, versus two for model (1). The
regression is again signiﬁcant under F-test at 1% level. Overall, adjusted R2 for model (2)
is higher than adjusted R2 for basic model (1) (65% versus 71%). This improvement in
explanatory power of the regression indicates that reporting of R&D is a significant factor
in the statistical explanation of market value of equity.
Table 4: Value relevance of R&D over the period 2005-2015
Variable
Coefficient
Basic Model 1
Table 4: Value relevance of R&D over the period 2005-2015
E Variable
2.084** Coefficient
BV
0.890**
Basic Model 1
Intercept
0.638***
2.084**
E
144
F BV
0.890**
Adjusted
R2
0.638***
Intercept
N F
144
Adjusted
R2 Model 2
Decomposed
AE N
2. 912***
ABV Decomposed Model 2
0.416***
AE
ExpRD
2.896*** 2. 912***
0.416***
ABV
CapRD
-1.332
2.896***
ExpRD
Intercept
0.719**
-1.332
CapRD
121
F Intercept
0.719**
Adjusted
R2
121
F
N Adjusted R2

t value
2,97
t value
2,61
5.222,97
6.382,61
0.655.22
3966.38

P>|t|

P>|t| 0,004
0,009
0,0040,000
0,0090.000

0,000
0.000

0.65
6,02396
3,22
4,566,02
3,22
-0,30
4,56
2.52
-0,30
7.612.52
0.717.61
3960.71

0,000
0,000
0,0000,000
0,000
0,081
0,000
0,0810,002
0,0020.000

0.000

396 i at time t. BV stands for book
MV N
is the market value for company i at time t. E is the earnings of company
MV is the market value for company i at time t. E is the earnings of company i at time t. BV stands for book value of equity of company i at
value of equity of company i at time t. AE is the adjusted earnings for firm i in year t, before the processing
time t. AE is the adjusted earnings for firm i in year t, before the processing of R&D expenditure. ABV represents the adjusted book value of
of R&D
expenditure. ABV represents the adjusted book value of equity for firm i in year t, which is net of
equity for firm i in year t, which is net of capitalized R&D. CapRD is the annual amount of capitalized R&D costs. ExpRD is the annual
capitalized
R&D. CapRD is the annual amount of capitalized R&D costs. ExpRD is the annual amount of
amount of expensed R&D costs. All variables are deflated by the number of ordinary outstanding shares. The models are with fixed effects and
expensed
R&D costs. All variables are deflated by the number of ordinary outstanding shares. The models are
control of heteroscedasticity.
withunder
fixed
effects and under control of heteroscedasticity.
Model 1:
Model 1: �� = � + � � + � �� + �
Model 2 :
Model
2: �� = � + � �� + � ��� + � ����� + � ����� + �
*** and ** indicate statistical significance at the 1% and 5% level, respectively.
*** and ** indicate statistical signiﬁcance at the 1% and 5% level, respectively.
The estimation results for the period after adoption of IFRS (2005-2015) show that the

Thevariables
estimation
forearnings,
the period
after
IFRS
show
equityresults
capital and
adjusted
foradoption
R&D costs,ofkeep
their(2005-2015)
positive relation
to thethat the
market equity
value, revealing
that accounting
always
provide
relevant
information
even after
variables
capital and
earnings,numbers
adjusted
for R&D
costs,
keep
their positive
relation to
expenditure.
the isolating
marketR&D
value,
revealing that accounting numbers always provide relevant information
even after isolating R&D expenditure.
Focusing on the main variables of interest (CapRD and ExpRD), table 4 reveals that the
coefficient for expensed R&D costs is significant, while it is insignificant for capitalized ones.
ExpRD have a positive impact on share price, revealing that, from the investors’ point of view,
these expenses provide relevant information after the adoption of the international IAS/IFRS
standards in France. Unlike previous studies (Shortridge, 2004; Tsoligkas and Tsalavoutas, 2011)
where market participants perceive that expensed R&D only contains unsuccessful projects that
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Focusing on the main variables of interest (CapRD and ExpRD), table 4 reveals that the
coefficient for expensed R&D costs is significant, while it is insignificant for capitalized
ones. ExpRD have a positive impact on share price, revealing that, from the investors’
point of view, these expenses provide relevant information after the adoption of the
international IAS/IFRS standards in France. Unlike previous studies (Shortridge, 2004;
Tsoligkas and Tsalavoutas, 2011) where market participants perceive that expensed R&D
only contains unsuccessful projects that give no future benefit, but reduces the firm’s value
in the same way as any other cost, these expenses are well appreciated by investors in
French market after IFRS adoption.
On the other hand, capitalized R&D costs are not associated with market news.
Actually, the results show that CapRD costs are negatively but insignificantly related to
MV. Therefore, R&D capitalization has different effects on price compared to any other
asset. Actually, one euro increase in any asset is associated with an increase in share
price, whereas one euro increase in a R&D asset has not an effect on share price. The
insignificant coefficient reported in Table 4 (coef. = -1.332 ; t value = -0.30) means that
R&D capitalization is not associated with “good” or “bad” news, suggesting that investors
in French companies do not value R&D assets after IFRS implementation, while they
did it prior 2005. Actually, Cazavan-Jeny and Jeanjean (2006) report a negative impact
of capitalized R&D expenditure on market value for French firms in a period preceding
IFRS adopting (1993-2002).
Consequently, we can deduce from this non association between CapRD and the market
value that, in a period which made mandatory the capitalization of R&D, there is not
value relevance of capitalized R&D costs. This result is consistent with our hypothesis
H1 implying that R&D reporting does not create value for French firms under IFRS.
Our finding is in line with the idea of Stark (2008) arguing that the adoption of IFRS
would hinder the value relevance of R&D treatment. Actually, the adoption of IFRS
would remove management discretion in the treatment of R&D costs, so eliminating
a way that companies use to communicate information to stock markets by choosing
between expensing or capitalizing R&D expenditure. Actually since 2005, managers
are required to capitalize R&D expenditure (development costs) provided certain
criteria are met. In other words, reported capitalized R&D expenses are effectively value
relevant under the optional capitalization rule, and not in the context of a mandatory
adoption. Our result is also consistent with the idea of Wyatt (2008), suggesting that
the most discretionary items of intangible assets are the most relevant due to discretion
in the accounting treatment. The finding is in line with Gong and Wang (2016),
offering evidence that countries switching from the mandatory expensing or optional
capitalization rule to IFRS (the case of France) see decreases in the value relevance of
R&D costs as capitalizing R&D expenditure with future economic beneﬁts is mandatory
under IFRS.
In summary, it is found that R&D expenses disclosure, regulated by the IAS, contains
value-relevant information in the expensed portion of R&D and not in the capitalized
one. This finding can be explained by the fact that, once the management discretion is
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constrained by the adoption of the IAS, market participants consider and believe more on
expensed R&D costs than on the capitalized R&D expenditure.
4.2. RESULTS FOR THE INDUSTRY MEMBERSHIP EFFECTS ON VALUE
RELEVANCE OF R&D
Our third model is used to test Hypothesis H2 in order to examine the value relevance
of R&D expenses (capitalized or expensed) under the control of industry membership,
namely manufacturing and nonmanufacturing. Adjusted R2 are relatively high and very
close in both samples (0.66 and 0.67) indicating the same strong relationship between
accounting numbers and share prices whatever the industry. In the case of manufacturing
firms, the coefficient of expensed R&D costs (ExpRD) is positive and significant, whereas
it is insignificant in the case of nonmanufacturing companies.
On the other hand, results show that CapRD variable is insignificantly correlated with
the company’s market value for both nonmanufacturing and manufacturing sectors, and
there is no signiﬁcant difference between their coefficients (Table 5). This indicates that
R&D does not generate intangible assets for both industries. Overall, our results partially
support Hypothesis H2 stipulating that association between R&D expenditure and market
value does not depend on activity area. Actually, significant difference between both
sectors only exists in expensed R&D portions, as we observe a value relevance of expensed
R&D costs for manufacturing firms against to nonmanufacturing sector. The results are
similar to Shah et al. (2013) revealing that R&D expenditure is positively related to market
activity
area.
significant
difference between both sectors only exists in expensed R&D
value
only
forActually,
manufacturing
sector.
portions, as we observe a value relevance of expensed R&D costs for manufacturing firms
against to nonmanufacturing sector. The results are similar to Shah et al. (2013) revealing that
Table
5: Value relevance of R&D - sector effects (model 3)
R&D expenditure is positively related to market value only for manufacturing sector.
Manufacturing
Nonmanufacturing
firms
Table 5: Value relevance
of R&D -firms
sector effects
(model 3)
AE
ABV
AE
ExpRD
ABV
CapRD
ExpRD
Intercept
CapRD
F
Intercept
Adjusted R2
F
N
Adjusted
R2

Difference
Coefficient
t value firmsCoefficient
t value
CoefficientDifference
t value
Manufacturing
Nonmanufacturing
firms
2. 912***
3.02
1.310***
4.25
1.602
1.12
Coefficient 4.22 t value 0.961***
Coefficient 3.11 t value
Coefficient
t-0.96
value
0.416***
-0.545
2. 912*** 4.56 3.02 3.201
1.310*** 1.13 4.25
1.602
1.12
2.236***
-0.965*
-1.79
0.416***
4.22
0.961***
3.11
-0.545
-0.96
-1.963
-1.14
-1.336
-0.98
-0.627
-0.30
2.236***
4.56
3.201
1.13
-0.965*
-1.79
0.519***
5.28
0.931***
5.33
-0.412
-1.21
-1.963
-1.14
-1.336
-0.98
-0.627
-0.30
82***
54***
0.519***
5.28
0.931***
5.33
-0.412
-1.21
0.66 82***
0.67 54***
297 0.66
99 0.67

99earnings for firm i in year t, before the
N is the market value for company297
MV
i at time t. AE is the adjusted
MV is the market value for company i at time t. AE is the adjusted earnings for firm i in year t, before the processing of R&D expenditure. ABV
processing of R&D expenditure. ABV represents the adjusted book value of equity for firm i in year t, which is
represents the adjusted book value of equity for firm i in year t, which is net of capitalized R&D. CapRD is the annual amount of capitalized R&D
net of capitalized R&D. CapRD is the annual amount of capitalized R&D costs. ExpRD is the annual amount of
costs. ExpRD is the annual amount of expensed R&D costs. SEC is a dummy variable which is equal to 0 if firm i is a nonmanufacturing one, and
expensed R&D costs. SEC is a dummy variable which is equal to 0 if firm i is a nonmanufacturing one, and equal
equal to 1 if it is a manufacturing one. All variables are deflated by the number of ordinary outstanding shares. The model is with fixed effects and
to 1 if it is a manufacturing one. All variables are deflated by the number of ordinary outstanding shares. The
under control of heteroscedasticity.
model is with fixed effects and under control of heteroscedasticity.
Model 3 :
Model 3: �� = � + � ��� + � �� + � �� × ��� + � ��� + � ���  × ��� + � ���_�� +
� ���_�� × ��� + � ���_�� + � ���_�� × ��� + �

*** and * indicate statistical signiﬁcance at the 1% and 10% level, respectively.
*** and * indicate statistical significance at the 1% and 10% level, respectively.

5. CONCLUSION
The subtle difference between French rule (GAAP) and IFRS regarding the accounting
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5. CONCLUSION
The subtle difference between French rule (GAAP) and IFRS regarding the accounting
treatment of R&D expenditure is that under IAS 38, the development phase of an internal
project shall be recognized as asset if six criteria are met. Therefore, the capitalization of R&D
expenses, which was an option under French GAAP, has become an obligation under IAS/
IFRS. In this paper, we explore if R&D expenses are value relevant for investors in French
companies listed on the SFB 120 after adopting IFRS and for a recent period 2005-2015.
The results indicate that, against the concerns that the adoption of IFRS may lead to more
value relevant R&D reporting, the mandatorily capitalized portion of R&D expenditure
is not value relevant. This was not the case under French GAAP (Cazavan-Jeny and
Jeanjean, 2006). Nevertheless, expensed portion of R&D costs is positively associated with
the market value of the firms, revealing that investors don’t treat the expensed portion of
R&D as an association with unsuccessful R&D projects, as it was revealed by almost all
previous studies.
Following the transition to IFRS, there are sector related valuation differences regarding
R&D costs in French companies. Actually, the expensed portion of R&D is significantly
value relevant only for manufacturing companies. Relating to our findings, we conclude
that our results reject the expectations of Barth et al. (2008) and Ball (2006) that IFRS
better reflect companies’ fundamentals and support the argument advanced by Stark
(2008) and Wyatt (2008) that the adoption of IFRS would hinder the value relevance of
R&D reporting. The argument behind is that eliminating the discretion to treat R&D
expenditure would remove a useful way by which a company conveys information to the
stock market (Stark, 2008).
Overall, this research examines the value relevance of R&D expenditure during recent
period 2005-20015, which fulﬁlls a gap in the relevant literature for French market. To the
best of our knowledge, this is the ﬁrst study on the value relevance of R&D expenditure
involving post-IFRS period in France. A way to research, future studies can develop this
issue by examining other interesting markets such as China which in 2007 adopted a set
of accounting standards entirely new, Brazil which applied IFRS in 2010, or Canada, India
and Korea that have just implemented IFRS in 2011.
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